Xbrane and Stada Arz look to co-develop Lucentis biosimilar

13 July 2018

Swedish firm Xbrane Biopharma (Nasdaq OMXS: XBRANE) and Germany’s Stada Arzneimittel (SAZ: Xetra) have linked up to co-develop Xlucane, a biosimilar version of top-selling ophthalmic drug Lucentis (ranibizumab), which is marketed by Swiss pharma giants of Novartis (NOVN: VX) and Roche’s (ROG: SIX).

News of the deal saw Xbrane’s shares leap 28.67% to 63.50 Swedish kronor in morning trading, while Stada was virtually unchanged.

The collaboration between Xbrane and Stada is based on a co-development agreement, meaning that the companies will equally contribute to development expenses and share profits from commercialization in a 50/50 split. To enter into this agreement, Stada will make an upfront payment to Xbrane of 7.5 million euros ($8.8 million).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK